ArticleAnnals of surgical oncology2026
Prognostic Impact of Lymphovascular Invasion in Resected Pathological Stage I Invasive Non-small Cell Lung Cancer: A Propensity Score-Matched Cohort Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Lymphovascular Invasion as a Marker of Systemic Recurrence Risk in Stage I NSCLC.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLymphovascular invasion (LVI) is a potential adverse prognostic factor in early-stage non-small-cell lung cancer (NSCLC), but its independent value in pathological stage I invasive carcinoma remains undefined.
methodsPatients with pathological stage I invasive NSCLC who underwent resection between 2011 and 2024 were identified from the West China Lung Cancer Database. Propensity score matching (1:2, caliper = 0.2 standard deviations of the estimated propensity score) balanced clinicopathological covariates. Survival outcomes (recurrence-free survival, overall survival, cancer-specific survival) were analyzed using Cox regression. Competing-risk models explored recurrence patterns.
resultsAmong 4622 included patients, 200 were LVI-positive and 4422 were LVI-negative. After matching (183 LVI-positive, 343 LVI-negative), LVI positivity was independently associated with worse recurrence-free survival (hazard ratio [HR] 1.91, P = 0.002), overall survival (HR 2.58, P = 0.003), and cancer-specific survival (HR 3.39, P = 0.002). LVI-positive patients had a higher risk of distant metastasis (HR 2.51, P < 0.001), whereas no significant difference was observed for local/regional recurrence (HR 1.43, P = 0.294).
conclusionsIn resected pathological stage I invasive NSCLC, LVI is an independent adverse prognostic factor, driven predominantly by distant metastasis. The prognostic impact of LVI appeared more pronounced in patients without visceral pleural invasion. These findings support routine LVI reporting and risk-adapted postoperative surveillance.
Indexed as
Identifiers
42704565What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.